On the opposite side, the roles of FCER1A and FNTA in cancer and therapeutic resistance have not been well studied and thus could be novel markers of therapeutic resistance in CML. This evidence concerns the gene FCER1A and chronic myelogenous leukemia, BCR-ABL1 positive.